published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsHung et al., 2020 (REV) 2.11 [0.04; 108.31] Nojomi, 2020 2.04 [0.18; 23.27] Nojomi, 2020 (REV) 2.04 [0.18; 23.27] Solaymani-Dodaran, 2021 (REV) 0.82 [0.44; 1.51] 0.92[0.52; 1.64]Hung et al., 2020 (REV), Nojomi, 2020, Nojomi, 2020 (REV), Solaymani-Dodaran, 2021 (REV)40%700moderatenot evaluable clinical improvementdetailed resultsHuang, 2020 (REV) 0.73 [0.39; 1.37] Hung et al., 2020 (REV) 0.26 [0.11; 0.60] 0.45[0.16; 1.26]Huang, 2020 (REV), Hung et al., 2020 (REV)273%149moderatenot evaluable clinical improvement (14-day)detailed resultsHuang, 2020 (REV) 0.73 [0.39; 1.37] 0.73[0.39; 1.37]Huang, 2020 (REV)10%22NAnot evaluable clinical improvement (time to event analysis only)detailed resultsHung et al., 2020 (REV) 0.26 [0.11; 0.60] Solaymani-Dodaran, 2021 (REV) 1.06 [0.85; 1.33] 0.55[0.14; 2.24]Hung et al., 2020 (REV), Solaymani-Dodaran, 2021 (REV)290%507moderatenot evaluable hospital dischargedetailed resultsHuang, 2020 (REV) 0.50 [0.29; 0.87] 0.50[0.29; 0.87]Huang, 2020 (REV)10%22NAnot evaluable mechanical ventilationdetailed resultsSolaymani-Dodaran, 2021 (REV) 0.62 [0.32; 1.18] 0.62[0.32; 1.18]Solaymani-Dodaran, 2021 (REV)10%373NAnot evaluable radiologic improvement (14-day)detailed resultsHuang, 2020 (REV) 0.75 [0.53; 1.06] 0.75[0.53; 1.06]Huang, 2020 (REV)10%22NAnot evaluable radiologic improvement (7-day)detailed resultsHuang, 2020 (REV) 0.42 [0.04; 3.91] 0.42[0.04; 3.91]Huang, 2020 (REV)10%22NAnot evaluable viral clearance detailed resultsHuang, 2020 (REV) 0.83 [0.54; 1.29] Hung et al., 2020 (REV) 0.23 [0.10; 0.54] 0.46[0.13; 1.63]Huang, 2020 (REV), Hung et al., 2020 (REV)286%149moderatenot evaluable viral clearance (time to event analysis only)detailed resultsHung et al., 2020 (REV) 0.23 [0.10; 0.54] 0.23[0.10; 0.54]Hung et al., 2020 (REV)10%127NAnot evaluable viral clearance by day 14detailed resultsELACOI (Lopinavir/ritonavir), 2020 (REV) 0.54 [0.12; 2.48] Huang, 2020 (REV) 0.92 [0.80; 1.06] 0.91[0.79; 1.05]ELACOI (Lopinavir/ritonavir), 2020 (REV), Huang, 2020 (REV)20%91moderatenot evaluable viral clearance by day 7detailed resultsELACOI (Lopinavir/ritonavir), 2020 (REV) 0.92 [0.35; 2.47] Huang, 2020 (REV) 0.83 [0.42; 1.67] 0.86[0.49; 1.52]ELACOI (Lopinavir/ritonavir), 2020 (REV), Huang, 2020 (REV)20%91moderatenot evaluable ICU admissiondetailed resultsSolaymani-Dodaran, 2021 (REV) 0.81 [0.46; 1.44] 0.81[0.46; 1.44]Solaymani-Dodaran, 2021 (REV)10%373NAnot evaluable severe COVID-19 occurrencedetailed resultsELACOI (Lopinavir/ritonavir), 2020 (REV) 3.28 [0.79; 13.64] 3.28[0.79; 13.64]ELACOI (Lopinavir/ritonavir), 2020 (REV)10%69NAnot evaluable serious adverse eventsdetailed resultsHung et al., 2020 (REV) 4.28 [0.14; 130.10] 4.28[0.14; 130.10]Hung et al., 2020 (REV)10%127NAnot evaluable adverse eventsdetailed resultsHuang, 2020 (REV) 0.56 [0.04; 7.21] 0.56[0.04; 7.21]Huang, 2020 (REV)10%22NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-03-29 00:52 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 509 - roots T: 290